Sirona Biochem Advances Antiviral Research with New Compound Candidates for ICGEB Testing

Collaborative Effort Expands Antiviral Research through ICGEB Testing of Sirona Biochem's Latest Compound Candidates

Sirona Biochem Corp is excited to announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). Sirona Biochem is a cosmetic ingredient and drug discovery company with proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. 

Established in 1983 as a special project of UNIDO, the International Centre for Genetic Engineering and Biotechnology – ICGEB is an independent intergovernmental organization with HQ in Trieste (Italy) and with additional laboratories in New Delhi (India) and Cape Town (South Africa). It counts almost 70 Member States. The ICGEB is a not-for-profit IGO – any revenues generated are re-invested in research and in the funding programs for capacity building in its Member States. The Vision of the ICGEB is to be the world’s leading intergovernmental Organization for research, training, and technology transfer in the field of Life Sciences and Biotechnology.

The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology.

Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month.

Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases.

Published on : 29th June, 2023